In pregnant women with elevated leucine aminopeptidase, the patient may continue to observe the condition if it is occasional and should continue to have blood drawn for leucine aminopeptidase after one month. If the elevation is progressive, other systems and organs should be examined for the possibility of neoplastic disease. Leucine aminopeptidase, called LAP in the abbreviation of the test, is a protein enzyme that is abundant in the liver. When a patient has dilated and stagnant bile ducts inside and outside the liver, there will be an increase in LAP, especially if the patient has biliary stasis due to neoplastic disease. If patients have liver tumors or inflammation of the liver, as well as neoplastic diseases of the mammary gland reproductive system, they will have elevated LAP. In addition, for cirrhosis, infectious hepatitis, and chronic viral hepatitis, the LAP is generally elevated by about 2-4 times the normal value. For obstructive jaundice, the elevation is generally more pronounced, up to five times or more. The test results are more sensitive, and in addition to blood testing, LAP can also be detected in urine, so it is easier to collect blood samples as well as specimens for the test. The results also need to be combined with other tests among the liver function, as well as tumor markers.